Compass Therapeutics Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company, has a clinical trial catalyst to watch this quarter.
The company's lead drug candidate is Tovecimig (formerly CTX-009), a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A (VEGF-A) signaling pathways. Both of these are critical to angiogenesis and tumor vascularization.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.